NeuroBo Pharmaceuticals (NASDAQ:NRBO) Coverage Initiated at Maxim Group

Analysts at Maxim Group began coverage on shares of NeuroBo Pharmaceuticals (NASDAQ:NRBO) in a research note issued on Wednesday, Benzinga reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. Maxim Group’s price objective indicates a potential upside of 160.42% from the company’s current price.

NeuroBo Pharmaceuticals Stock Performance

NeuroBo Pharmaceuticals stock remained flat at $3.84 during midday trading on Wednesday. The company had a trading volume of 863 shares, compared to its average volume of 948,497. The stock has a fifty day simple moving average of $4.20 and a two-hundred day simple moving average of $3.96. NeuroBo Pharmaceuticals has a 12-month low of $2.89 and a 12-month high of $6.75.

NeuroBo Pharmaceuticals Company Profile

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.